A Phase 2 interventional study of adalimumab and Placebo in Hidradenitis Suppurativa, sponsored by Abbott. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-09.
Sponsored by Abbott · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 44th largest by enrollment of the 139 interventional ones that give a count, is the only one that started in 2009, is one of 61 in phase 2, and was the 7th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Spyre Therapeutics, Inc. · Sites in United States, Canada
Ages 18–75
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Harrison Dermatology · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 1 study filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.
This Phase 2 randomized, double-blind, placebo-controlled multicenter study consists of 2 treatment periods: a 16-week double-blind, placebo-controlled period (Period 1: Weeks 0 through the end of Week 15) followed by a 36-week open-label period (Period 2: Weeks 16 through 52). Participants are randomized in a 1:1:1 ratio based on Hurley Stage as stratification factor to receive adalimumab 40 mg every week (qwk), adalimumab 40 mg every other week (eow), or matching placebo during Period 1. During Period 2, participants receive open-label adalimumab 40 mg eow with the option to escalate to 40 mg weekly dosing at Week 28 or Week 31 if the participant has a Physician's Global Assessment of moderate disease or worse (score of greater than or equal to 3). The primary objective of the study is to determine the clinical efficacy and safety of participants with moderate to severe chronic hidradenitis suppurativa (HS) after 16 weeks of treatment. The secondary objective is to evaluate the maintenance of efficacy and continued safety of adalimumab for an additional 36 weeks of treatment. (Note: Hurley Stage is a classification system for skin involvement that is largely based on the presence and extent of abscess formation accompanied by scarring and sinus tracts. Hurley Stages are I [abscess formation without scarring and sinus tracts], II [widely separated recurrent abscesses with scarring and sinus tracts], and III [multiple interconnected abscesses and sinus tracts across entire area]. Randomization in this study was performed using stratification by Hurley Stage [III versus (I or II).) At the present time, Period 1 double-blind data only is provided; additional information will be provided when analysis of open-label Period 2 is completed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.
Biological: adalimumab
Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.
Biological: adalimumab
Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.
Drug: Placebo
Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
Also known as: ABT-D2E7, Humira
Subcutaneous injection using prefilled syringe containing 0.8 milliliters
Percentage of Participants Achieving Clinical Response at Week 16
Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).
Time frame: Baseline, Week 16
Percent Change From Baseline in Number of All Inflammatory Nodules and Plaques at Week 16
Includes inflammatory nodules that are tender, erythematous, and have diameters less than 5 cm and includes plaques that have diameters greater than or equal to 5 cm. Range for percent change is negative infinity to infinity. Negative percent changes from Baseline indicate improvement.
Time frame: Baseline, Week 16
Percentage of Participants Achieving Clinical Response at Week 2
Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).
Time frame: Baseline, Week 2
Percentage of Participants Achieving Clinical Response at Week 4
Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).
Time frame: Baseline, Week 4
Percentage of Participants Achieving Clinical Response at Week 8
Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).
Time frame: Baseline, Week 8
Percentage of Participants Achieving Clinical Response at Week 12
Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).
Time frame: Baseline, Week 12
Change From Baseline in Modified Sartorius Scale at Week 16
The Modified Sartorius Scale reflects changes in hidradenitis suppurative symptoms, namely the number of lesions (abscesses, nodules, and fistulas) and the longest distance between lesions. A total score is derived based on assessments at up to 8 distinct anatomical regions and ranges from 5 to indefinite. Smaller numbers are better scores and indicate less lesion involvement, thus decreases (negative changes) from baseline indicate improvement in severity of disease.
Time frame: Baseline, Week 16
Change From Baseline in Modified Sartorius Scale at Week 52
The Modified Sartorius Scale reflects changes in hidradenitis suppurative symptoms, namely the number of lesions (abscesses, nodules, and fistulas) and the longest distance between lesions. A total score is derived based on assessments at up to 8 distinct anatomical regions and ranges from 5 to indefinite. Smaller numbers are better scores and indicate less lesion involvement, thus decreases (negative changes) from baseline indicate improvement in severity of disease.
Time frame: Baseline, Week 52
Percent Change From Baseline in Number of All Inflammatory Nodules and Plaques at Week 52
Includes inflammatory nodules that are tender, erythematous, and have diameters less than 5 cm and includes plaques that have diameters greater than or equal to 5 cm. Range for percent change is negative infinity to infinity. Negative percent changes from Baseline indicate improvement.
Time frame: Baseline, Week 52
| Milestone | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB |
|---|---|---|---|
| Started | 51 | 52 | 51 |
| Completed | 45 | 52 | 46 |
| Not completed | 6 | 0 | 5 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 |
| Withdrew: Exceeded allowed number of interventions | 0 | 0 | 1 |
| Withdrew: Non-compliance | 1 | 0 | 0 |
| Withdrew: Investigator discretion | 1 | 0 | 0 |
Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).
| percentage of participants | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Response at Week 16 | 17.6 | 9.6 | 3.9 |
Includes inflammatory nodules that are tender, erythematous, and have diameters less than 5 cm and includes plaques that have diameters greater than or equal to 5 cm. Range for percent change is negative infinity to infinity. Negative percent changes from Baseline indicate improvement.
| percent change | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB |
|---|---|---|---|
| Percent Change From Baseline in Number of All Inflammatory Nodules and Plaques at Week 16 | -50.66 ± 11.364 | -30.43 ± 11.452 | -13.66 ± 11.452 |
Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).
| percentage of participants | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Response at Week 2 | 2.0 | 9.6 | 2.0 |
Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).
| percentage of participants | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Response at Week 4 | 11.8 | 5.8 | 2.0 |
Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).
| percentage of participants | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Response at Week 8 | 7.8 | 5.8 | 7.8 |
Clinical response is defined as a Physician's Global Assessment (PGA) of clear, minimal, or mild (scores of 0, 1, or 2) with a minimum of 2 grades improvement (reduction) from baseline. PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe).
| percentage of participants | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Response at Week 12 | 21.6 | 7.7 | 5.9 |
The Modified Sartorius Scale reflects changes in hidradenitis suppurative symptoms, namely the number of lesions (abscesses, nodules, and fistulas) and the longest distance between lesions. A total score is derived based on assessments at up to 8 distinct anatomical regions and ranges from 5 to indefinite. Smaller numbers are better scores and indicate less lesion involvement, thus decreases (negative changes) from baseline indicate improvement in severity of disease.
| scores on a scale | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB |
|---|---|---|---|
| Change From Baseline in Modified Sartorius Scale at Week 16 | -30.0 ± 53.82 | -16.0 ± 82.54 | -7.5 ± 47.78 |
The Modified Sartorius Scale reflects changes in hidradenitis suppurative symptoms, namely the number of lesions (abscesses, nodules, and fistulas) and the longest distance between lesions. A total score is derived based on assessments at up to 8 distinct anatomical regions and ranges from 5 to indefinite. Smaller numbers are better scores and indicate less lesion involvement, thus decreases (negative changes) from baseline indicate improvement in severity of disease.
Results for this outcome have not been posted.
Includes inflammatory nodules that are tender, erythematous, and have diameters less than 5 cm and includes plaques that have diameters greater than or equal to 5 cm. Range for percent change is negative infinity to infinity. Negative percent changes from Baseline indicate improvement.
Results for this outcome have not been posted.
Collected over For the 3 treatment groups in Period 1 (Adalimumab 40 mg Qwk, Adalimumab 40 mg Eow, and Placebo): Week 0 up to Week 16. For Open-label adalimumab (Period 2): Week 16 through Week 52 plus 70 days after the last dose.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab 40 mg Qwk DB | — | 4/51 (7.8%) | 36/51 (70.6%) |
| Adalimumab 40 mg Eow DB | — | 3/52 (5.8%) | 33/52 (63.5%) |
| Placebo DB | — | 2/51 (3.9%) | 30/51 (58.8%) |
| Event | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/51 | 0/52 | 0/51 |
| Small intestinal obstructionGastrointestinal disorders | 0/51 | 0/52 | 1/51 |
| Non-cardiac chest painGeneral disorders | 1/51 | 0/52 | 0/51 |
| Escherichia infectionInfections and infestations | 1/51 | 0/52 | 0/51 |
| Genital infection bacterialInfections and infestations | 1/51 | 0/52 | 0/51 |
| Vocal cord neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/51 | 0/52 | 0/51 |
| Suicide attemptPsychiatric disorders | 0/51 | 0/52 | 1/51 |
| Pilonidal cystInfections and infestations | 0/51 | 1/52 | 0/51 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/51 | 1/52 | 0/51 |
| HidradenitisSkin and subcutaneous tissue disorders | 0/51 | 1/52 | 0/51 |
| Event | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB |
|---|---|---|---|
| HeadacheNervous system disorders | 8/51 | 7/52 | 2/51 |
| NasopharyngitisInfections and infestations | 6/51 | 7/52 | 6/51 |
| HidradenitisSkin and subcutaneous tissue disorders | 4/51 | 6/52 | 6/51 |
| NauseaGastrointestinal disorders | 4/51 | 2/52 | 1/51 |
| Upper respiratory tract infectionInfections and infestations | 4/51 | 4/52 | 2/51 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 3/51 | 0/52 | 0/51 |
| VomitingGastrointestinal disorders | 1/51 | 2/52 | 3/51 |
| FatigueGeneral disorders | 3/51 | 2/52 | 2/51 |
| FolliculitisInfections and infestations | 0/51 | 0/52 | 3/51 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/51 | 0/52 | 1/51 |
| Age Continuous(years) | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB | Total |
|---|---|---|---|---|
| Mean | 35.1 ± 10.69 | 36.1 ± 12.50 | 37.8 ± 12.10 | 36.3 ± 11.76 |
| Sex: Female, Male(Participants) | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB | Total |
|---|---|---|---|---|
| Female | 36 | 38 | 36 | 110 |
| Male | 15 | 14 | 15 | 44 |
| Region of Enrollment(participants) | Adalimumab 40 mg Qwk DB | Adalimumab 40 mg Eow DB | Placebo DB | Total |
|---|---|---|---|---|
| United States | 41 | 39 | 36 | 116 |
| Europe | 10 | 13 | 15 | 38 |
The record gives a start of Apr 2009, a primary completion of Mar 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab